Sotyktu

Graphic image of an arrow nailing the bullseye of a target
Biotech

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Phase 3 psoriasis studies of Alumis’ TYK2 inhibitor hit their primary endpoints, setting the biotech up to file for approval of a Sotyktu challenger.
Nick Paul Taylor Jan 6, 2026 9:05am
Takeda

Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib

Dec 18, 2025 7:55am
crown royalty king queen win

J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial

Sep 17, 2025 9:45am
scrabble tiles spelling out psoriasis

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu

Mar 10, 2025 7:30am
decision path change of plans arrows business decision

BMS backs out of Dupixent fight, axing asset despite phase 3 win

Feb 7, 2025 6:26am
Graphic image of the letters IPO in white in front of a yellow background

Alumis plans IPO to fund TYK2 inhibitor through phase 3 trials

Jun 10, 2024 8:35am